Skip navigation
Watchlist Sponsored By :


Current DateTime: 06:57:31 12 Nov 2009
LinksList Documentid: 33482595

Current DateTime: 06:57:31 12 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 06:57:31 12 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 06:57:31 12 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Recession Nerves = Great Buying Opportunity
By: Andrew Fisher | 06 Feb 2008 | 03:01 PM ET
Text Size

Picks and Pans

David Spika, WHG Funds vice president, isn't afraid to use the "R" word -- but he's no bear.  He thinks the recession talk is overdone, making now a great time to buy stocks.

Jeff Krumpelman of Fifth Third Asset Management also hears opportunity knocking.

"I think the market is confused and nervous about how far left or right we are of zero," Krumpelman told CNBC.

"So we'll have continued volatility while it's figuring that out. But if you ask me over the next nine to 12 months if I thought this is a good time to be building positions, absolutely, I think it is."

"The market's pretty much priced into a recession, and priced into a pretty significant recession," Spika said.  "Regardless of whether we have one, now is a good time to buy."

So what buys look good?  He likes The Walt Disney Co. [DIS  Loading...      ()   ]

"If the economy goes into a significant, protracted recession, consumer-related stocks are going to get hurt -- but we don't think that's the case, and Disney's trading at a 20-year low valuation right now," Spika said. 

"We think we'd be stupid not to be buying it here."

Krumpelman's confidence extends all the way to biotechnology.  One biotech stock that he likes even better than pharmaceuticals: Celgene [CELG  Loading...      ()   ].

"I think it's misleading just to say, let's flock to large-cap pharmaceutical companies that have very unimpressive growth rates." he said.  "I feel much safer with...Celgene."

He said the company "has a strong franchise, with a 35 percent growth profile."

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • They may have wrecked their companies or saved our economy. Tell us what you think.
  • Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
  • A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
  • Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
  • PepsiCo is ramping up its onsite health facilities for workers.
ADD COMMENTS
Remaining characters


Current DateTime: 02:33:17 12 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 11:27:47 12 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 05:29:42 12 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:00:12 12 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters